Application of microfluidic technologies on COVID-19 diagnosis and drug discovery

Acta Pharm Sin B. 2023 Feb 24;13(7):2877-2896. doi: 10.1016/j.apsb.2023.02.014. Online ahead of print.

Abstract

The ongoing coronavirus disease 2019 (COVID-19) pandemic has boosted the development of antiviral research. Microfluidic technologies offer powerful platforms for diagnosis and drug discovery for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) diagnosis and drug discovery. In this review, we introduce the structure of SARS-CoV-2 and the basic knowledge of microfluidic design. We discuss the application of microfluidic devices in SARS-CoV-2 diagnosis based on detecting viral nucleic acid, antibodies, and antigens. We highlight the contribution of lab-on-a-chip to manufacturing point-of-care equipment of accurate, sensitive, low-cost, and user-friendly virus-detection devices. We then investigate the efforts in organ-on-a-chip and lipid nanoparticles (LNPs) synthesizing chips in antiviral drug screening and mRNA vaccine preparation. Microfluidic technologies contribute to the ongoing SARS-CoV-2 research efforts and provide tools for future viral outbreaks.

Keywords: COVID-19; Detection; Drug screen; Lab-on-a-chip; Microfluidic; Organ-on-a-chip; SARS-CoV-2.

Publication types

  • Review